Conversion efficacy of intravenous ibutilide compared with intravenous amiodarone in patients with recent-onset atrial fibrillation and atrial flutter

International Journal of Cardiology

Volumn 118, Issue 3, 2007, Pages 321-325

  Kafkas, Nikolaos V ^a   Patsilinakos, Sotirios P ^a   Mertzanos, George A ^a   Papageorgiou, Kostas I ^a   Chaveles, John I ^a   Dagadaki, Ourania K ^a   Kelesidis, Kostas M ^a  

^a KAT HOSPITAL   (Greece)

Author keywords

Amiodarone; Atrial fibrillation flutter; Conversion; Ibutilide

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; DIGITALIS; DILTIAZEM; IBUTILIDE; PROPAFENONE; VERAPAMIL;

ADULT; ARTICLE; ATRIOVENTRICULAR JUNCTION ARRHYTHMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HUMAN; HYPOTENSION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MONOMORPHIC VENTRICULAR TACHYCARDIA; POLYMORPHIC VENTRICULAR TACHYCARDIA; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; REPOLARIZATION; SINUS RHYTHM; TORSADE DES POINTES;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; AMIODARONE; ATRIAL FIBRILLATION; ATRIAL FLUTTER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROBABILITY; PROSPECTIVE STUDIES; RECURRENCE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; SULFONAMIDES; TREATMENT OUTCOME;

EID: 34247609337     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2006.07.017     Document Type: Article

References (22)

1. Ryder K.M., and Benjamin E.J. Epidemiology and significance of atrial fibrillation. Am J Cardiol 84 9A (Nov. 4 1999) 131R-138R
2. Braunwald s heart disease: a textbook of cardiovascular medicine. Chapter 32 specific arrhythmias: diagnosis and treatment. 7th edition (2004) 803-863
3. Allessie M., and Bonke F. Experimental evaluation of Moes multiple wavelet hypothesis of atrial fibrillation. J Cardiovasc Electrophysiol (1985) 265
4. Garg A., and Feld G.K. Atrial Flutter. Curr Treat Options Cardiovasc Med 3 4 (2001) 277-289
5. Allessie M., Resna P., and Kirchoff C. The role of refractoriness, conduction velocity and wavelength in the initiation of atrial fibrillation in normal dogs. Pace 11 (1988) 901
6. Stambler B.S., Wood M.A., Ellenbogen K.A., et al. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter and fibrillation. Circulation 94 (1996) 1613-1621
7. Tai C.T., and Chen S.A. Mechanisms of antiarrhythmic drug action on termination of atrial flutter. Pacing Clin Electrophysiol 24 5 (May 2001) 824-834
8. Ellenbogen K.A., Stambler B.S., Wood M.A., et al., for the Ibutilide Investigators. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol 28 (1996) 130-136
9. Eversole A., Hancock W., Johns T., Lopez L.M., and Conti C.R. Ibutilide: efficacy and safety in atrial fibrillation and atrial flutter in a general cardiology practice. Clin Cardiol 24 7 (Jul 2001) 521-525
10. Gowda R.M., Khan I.A., Panukollu G., et al. Am J Ther 11 2 (Mar-Apr 2004) 95-97
11. Singh B.N., Mody F.V., Lopez B., and Sarma J.S. Antiarrhythmic Agents for atrial fibrillation: Focus on prolonging Atrial Repolarization. Am J Cardol 84 (Nov 4 1999) 161R-173R
12. Doggrell S.A., and Hancox J.C. Ibutilide-recent molecular insights and accumulating evidence for use in atrial flutter and fibrillation. Expert Opin Investig Drugs 14 5 (May 2005) 655-669
13. Ando G., Di Rosa S., Rizzo F., et al. Ibutilide for cardioversion of atrial flutter: efficacy of a single dose in recent-onset arrhythmias. Minerva Cardioangiol 52 1 (Feb 2004) 37-42
14. Viktorsdottir O., Henriksdottir A., and Arnar D.O. Ibutilide for treatment of atrial fibrillation in the emergency department. Emerg Med J 23 2 (Feb 2006) 133-134
15. Vardas P.E., Kochliadakis G.E., Igoumenidis N.E., Tsatsakis A.M., Simantirakis E.N., and Chlouverakis G.I. Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation. Chest 117 6 (2000) 1538
16. Sun J.L., Guo J.H., Zhang N., Zhang H.C., and Zhang P. Clinical comparison of ibutilide and propafenone for converting atrial flutter. Cardiovasc Drugs Ther 19 1 (Jan 2005) 57-64
17. Zhang N., Guo J.H., Zhang H.C.h., Li X.B., Zhang P., and Xn Y. Comparison of intravenous ibutilide vs. propafenone for rapid termination of recent onset atrial fibrillation. Int J Clin Pract 59 12 (Dec 2005) 1395-1400
18. Vos M.A., Golitsyn S.R., Stangl K., et al. Superiority of ibutilide (a new class III agent) over dl-sotalol in converting atrial flutter and atrial fibrillation. Heart 79 (1998) 568-575
19. Bernard E.O., Schmid E.R., Schmidlin D., Scharf C., Candinas R., and Germann R. Ibutilide versus amiodarone in atrial fibrillation: a double-blinded, randomized study. Crit Care Med 31 4 (Apr 2003) 1031-1034
20. Allessie M.A. Reentrant mechanisms underlying atrial fibrillation. In: Zipes D.P., and Jalife J. (Eds). Electrophysiology: from cell to bedside. 2nd ed. (1995), WB Saunders Co, Philadelphia, Pa 562-566
21. Stambler B.S., Wood M.A., and Ellenbogen K.A. Pharmacologic alterations in human type I atrial flutter length and monophasic action potential duration: evidence of a fully excitable gap in the reentrant circuit. J Am Coll Cardiol 27 (1996) 441-453
22. Cheng J., Glatter K., Yang Y., Zhang S., Lee R., and Scheinman M.M. Electrophysiological response of the right atrium to ibutilide during typical atrial Flutter. Circulation 106 7 (Aug 13 2002) 814-819